Skip to main content
Clinical Trials/NCT05069415
NCT05069415
Completed
Not Applicable

Visual Performance and Patient Satisfaction With A New Monofocal Intraocular Lens

Carolina Eyecare Physicians, LLC2 sites in 1 country75 target enrollmentOctober 4, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataract
Sponsor
Carolina Eyecare Physicians, LLC
Enrollment
75
Locations
2
Primary Endpoint
Binocular Distance-corrected Intermediate (66 cm) Visual Acuity at 3 Months.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study is a 3-month, prospective, up to 2 center, bilateral, randomized subject masked clinical evaluation of a monofocal intraocular lens (IOL) when both eyes are targeted for emmetropia and when the non-dominant eye is targeted for mini monovision (-0.75 D) in patients with or without astigmatism undergoing routine cataract surgery.

Registry
clinicaltrials.gov
Start Date
October 4, 2021
End Date
November 30, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is undergoing bilateral cataract extraction with intraocular lens implantation.
  • Willing and able to provide written informed consent for participation in the study
  • Willing and able to comply with scheduled visits and other study procedures.
  • Scheduled to undergo standard cataract surgery in both eyes within 6 - 30 days between surgeries.
  • Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.
  • Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion Criteria

  • Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
  • Uncontrolled diabetes.
  • Use of any systemic or topical drug known to interfere with visual performance.
  • Contact lens use during the active treatment portion of the trial.
  • Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
  • Clinically significant corneal dystrophy.
  • Irregular astigmatism.
  • History of chronic intraocular inflammation.
  • History of retinal detachment.
  • Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.

Outcomes

Primary Outcomes

Binocular Distance-corrected Intermediate (66 cm) Visual Acuity at 3 Months.

Time Frame: 3 months

Secondary Outcomes

  • Binocular Low Contrast Distance Visual Acuity at 3 Months(3 months)
  • Distance-corrected Near Visual Acuity at Best Distance at 3 Months(3 months)

Study Sites (2)

Loading locations...

Similar Trials